Cultivation
There’s No UK Cannabis Industry Without UK Cultivation
The UK economic growth faces a paradox of two seemingly opposing pressures, yet both may be resolved by moving in the same direction.
Celadon Pharmaceuticals
22stories
21 Novlast updated
More in Celadon Pharmaceuticals
- Markets & Stocks
Celadon’s Funding Woes Continue, DanCann Pharma Partners with Tetra Pharma, & Argent Bio Posts Positive Clinical Trial Results
UK-listed medical cannabis producer Celadon Pharmaceuticals is struggling to emerge from its precarious financial position after months of turmoil.
- Markets & Stocks
Celadon’s Shares Spike as Partnership Starts Generating Revenue, Phillip Morris Expands Cannabis Footprint, & More from DanCann Pharma
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”CEL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Celadon Pharmaceuticals has seen its stock price spike this week after revealing that its supply agreement with Danish firm Valeos is now ‘actively contributing to Celadon’s operations.’
- Markets & Stocks
Ananda and Celadon Raise Millions in New Funding, as Celadon Signs New Production Deal with Valeos, & More From Chill Brands
Ananda Developments [stock_market_widget type=”chart” template=”line” assets=”ANA.AQ” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The Aquis Stock Exchange-listed CBD life sciences company announced this week that it has successfully raised £2.1m through a new subscription of shares.
- Markets & Stocks
Celadon Sees 60% Drop in Stock Price as Funding Delayed, Hellenic Avoids Liquidation, & Flora Lists in Germany
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”CEL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The London Stock Exchange-listed medical cannabis operator saw its stock drop by nearly 60% this week, resulting in a dramatic downturn in its market capitalisation, after announcing that it has been forced to weather numerous delays in funding.
- Markets & Stocks
Tilray Gets First New German Domestic Cultivation Licence, Dalgety Seeks £6m Investment, & More from Celadon
Tilray [stock_market_widget type=”chart” template=”line” assets=”TLRY” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] US cannabis giant Tilray has become the first company in half a decade to recieve a new domestic cannabis cultivation licence in Germany.
- Markets & Stocks
Cantourage & Celadon Announce Double Digit Growth in 2023, Hellenic Dynamics Announces Further Fundraise
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”CEL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Celadon Pharmaceuticals this week released its full-year results for 2023, reporting revenues over three times those seen in 2022.
- Markets & Stocks
Celadon Secures £2M in Funding as It Makes Inaugural Product Delivery, Akanda Appoints New CFO, & Curaleaf Launches on TSX
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CEL.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Celadon Pharmaceuticals this week passed a ‘significant milestone’ as it completed its first ever supply delivery to clients, just days after the successful completion of a £2m fundraise through a placement of new ordinary shares.
- Markets & Stocks
Yooma Wellness Sells Last ‘Revenue Generating Asset’ Vitality CBD, Hellenic Nears Completion of Facility, & More from Celadon
Yooma Wellness Yooma Wellness this week announced that it had sold its last remaining revenue-generating asset as it warned that should it be unable to ‘secure additional sources of liquidity’, it could be forced into liquidation.
